ArticleCancer science2026
ZNF844 Suppresses Invasion and Metastasis in Nasopharyngeal Carcinoma by Inhibiting the PI3K-AKT Signaling Pathway.
Article in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Epigenetic regulation plays a crucial role in the development of nasopharyngeal carcinoma (NPC). However, the epigenetic mechanisms underlying NPC recurrence and metastasis remain poorly understood. This study aimed to investigate and identify a novel molecular target with prognostic relevance in NPC. The methylation status of zinc finger protein 844 (ZNF844) was assessed in NPC tissues and cell lines using bisulfite pyrosequencing. ZNF844 expression levels in NPC cell lines and clinical specimens were analyzed by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and Western blotting. Stable NPC cell lines with ZNF844 overexpression or knockdown were established to evaluate its biological functions both in vitro and in vivo. RNA sequencing was performed to identify downstream targets of ZNF844, followed by validation using qRT-PCR and Western blotting. We found that ZNF844 expression was significantly downregulated in NPC tissues and cell lines, correlating with hypermethylation of its promoter region. Treatment with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine (DAC) restored ZNF844 mRNA expression. ZNF844 overexpression suppressed NPC cell invasion and metastasis, whereas its silencing had the opposite effect. In xenograft models, ZNF844 overexpression reduced metastatic burden. ZNF844 inhibited the PI3K-AKT signaling pathway, thereby suppressing NPC cell invasiveness. Clinically, high ZNF844 expression was associated with improved overall survival and distant metastasis-free survival. ZNF844 inhibits the invasive and metastatic capabilities of nasopharyngeal carcinoma by modulating the PI3K-AKT signaling pathway. These inhibitory effects can be partially or completely reversed by treatment with SC79. It may serve as a promising therapeutic target and prognostic biomarker for NPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.